The Journal of clinical endocrinology and metabolism
The most recent articles from:
February 2013
-
J. Clin. Endocrinol. Metab. · Feb 2013
Randomized Controlled TrialBone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial.
Odanacatib, a cathepsin K inhibitor, increases spine and hip areal bone mineral density (BMD) in postmenopausal women with low BMD and cortical thickness in ovariectomized monkeys. ⋯ Over 2 years, odanacatib decreased bone resorption, maintained bone formation, increased areal and volumetric BMD, and increased estimated bone strength at both the hip and spine.